^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IRAK-4 inhibitor

    Related drugs:
    2ms
    Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib. (PubMed, Mol Cancer Ther)
    Emavusertib in combination with anti-PD-1 therapy results in improved tumor-infiltrating lymphocyte recruitment, decreased myeloid derived suppressor cell function, and upregulation of interferon γ signaling resulting in improved survival in aggressive mouse models of melanoma brain metastases. This work supports the development of combination strategies of emavusertib with immune checkpoint blockade in melanoma brain metastases.
    Journal • Checkpoint inhibition
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IFNG (Interferon, gamma) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
    |
    emavusertib (CA-4948)
    2ms
    A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, AbbVie
    New P1 trial
    |
    itraconazole
    2ms
    A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants (clinicaltrials.gov)
    P1, N=93, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion • Adverse events
    3ms
    CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=43, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    gemcitabine • albumin-bound paclitaxel • emavusertib (CA-4948)
    3ms
    CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=43, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • emavusertib (CA-4948)
    3ms
    CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer (clinicaltrials.gov)
    P1, N=42, Recruiting, Washington University School of Medicine | Trial completion date: Jun 2028 --> Apr 2029 | Trial primary completion date: Sep 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • leucovorin calcium • emavusertib (CA-4948)
    4ms
    IRAK4: A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus (clinicaltrials.gov)
    P1, N=28, Suspended, AstraZeneca | Recruiting --> Suspended
    Trial suspension
    |
    metformin
    4ms
    D7770C00001: A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms (2025-520786-44-00)
    P1/2, N=7, Suspended, AstraZeneca AB | Recruiting --> Suspended
    Trial suspension
    4ms
    D7860C00005: A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus (2025-522551-25-00)
    P1, N=28, Suspended, AstraZeneca AB | Recruiting --> Suspended
    Trial suspension
    |
    metformin
    4ms
    Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=48, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • emavusertib (CA-4948)
    5ms
    CA-4948 102: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1/2, N=366, Suspended, Curis, Inc. | Recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • SF3B1 (Splicing Factor 3b Subunit 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    FLT3 mutation • SF3B1 mutation
    |
    Venclexta (venetoclax) • emavusertib (CA-4948)
    5ms
    CA-4948-203: A Ph2 Study of Emavusertib + an Approved BTKi in Patients with CLL and Other B-cell Malignancies (2025-523600-68-00)
    P1/2, N=40, Not yet recruiting, Curis Inc.
    New P1/2 trial
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)